Home Merck Announces FDA Acceptance of New Drug Application for Investigational Fertility Treatment
 

Keywords :   


Merck Announces FDA Acceptance of New Drug Application for Investigational Fertility Treatment

2013-09-09 14:30:00| Merck.com - Research & Development News

Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the New Drug Application (NDA) for its investigational fertility treatment, corifollitropin alfa, has been accepted for standard review by the U.S. Food and Drug Administration (FDA). Merck is seeking FDA approval of corifollitropin alfa for Controlled Ovarian Stimulation (COS) in women participating in assisted reproductive technology. Language: English Contact: MerckMedia:Pam Eisele, 908-423-5042orTina Grasso, 267-893-9783orInvestors:Carol Ferguson, 908-423-4465 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: application treatment drug acceptance

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
25.1114
25.111/24 308 GTB
25.11! 3 DVD
25.11gt scr
25.11YONEX 3 3E
25.11 1000L
25.11M2514 Roland/ SH-201
25.1125th ANNIVERSARY GOLDEN BOX Amazon
More »